Introduction to GLP-1 Agonists GLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning with the FDA approval of AstraZenecas Byetta in 2005
The mechanism of action involves several physiological processes
Diabetes Care 36 , 23462350 (2013)
This, in turn, can contribute to better blood sugar control and support a healthy metabolism
10 Recently, several clinical trials have shown the potential effects of these medications in not only in glycemic control but also in the improvement of cardiovascular outcomes, weight loss, osteoarthritis, 11 metabolic dysfunctionassociated steatohepatitis (MASH), 12 Parkinsons disease, 13 chronic kidney disease (CKD) 14 and obstructive sleep apnea